Methyltransferase DNMT3B promotes colorectal cancer cell proliferation by inhibiting PLCG2

Yong Ji,Yang Wang,Jiacheng Zou,Guanghao Liu,Mingyu Xia,Jun Ren,Daorong Wang
DOI: https://doi.org/10.1101/2024.05.13.594025
2024-05-15
Abstract:Background: Aberrant DNA methylation patterns in the promoter region of PLCG2 have been associated with dysregulated signaling pathways and cellular functions. Its role in colorectal cancer cells is still unknown. Methods: qRT-PCR was used to examine DNMT3B expression in colorectal cancer. Western blot and immunohistochemistry were used to analyze DNMT3B and PLCG2 protein levels in colorectal tissues and cell lines. The cell counting kit-8 and colony experiments were used to identify the proliferation of colorectal cancer cells. Methylation-specific PCR (MSP) and bisulfite-sequencing PCR (BSP) was used to measure DNA methylation levels. Results: DNMT3B is overexpressed in colorectal cell in TCGA datasets and Kaplan-Meier plots. DNMT3B is significantly overexpressed in tumor tissues compared to adjacent non-tumor tissues. Western blotting results demonstrated high expression of DNMT3B in tumor tissues. Compared to normal colonic epithelial cells, colorectal cancer cell lines exhibited elevated levels of PLCG2 methylation. oePLCG2 effectively prevented the in vivo xenograft tumor growth of colorectal cancer. Conclusions: PLCG2 is identified as a key downstream regulatory protein of DNMT3B in colorectal cancer. DNMT3B Inhibits PLCG2 transcription through methylation of the PLCG2 promoter region. DNMT3B controls colorectal cancer cell proliferation through the PLCG2, which is useful for creating therapeutic approaches that target PLCG2 expression for the treatment of colorectal cancer.
Cancer Biology
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to explore the role and mechanism of DNA methyltransferase DNMT3B in colorectal cancer cell proliferation, especially the specific pathway by which DNMT3B promotes colorectal cancer cell proliferation by inhibiting PLCG2 (phospholipase C - γ2). Specifically, the research aims to: 1. **Verify the expression level of DNMT3B in colorectal cancer**: Analyze the TCGA database and clinical samples to confirm the high - expression of DNMT3B in colorectal cancer tissues and explore its relationship with patient prognosis. 2. **Explore the influence of DNMT3B on PLCG2**: Detect the regulatory effect of DNMT3B on PLCG2 expression by experimental means such as qRT - PCR, Western blot, immunohistochemistry, etc. 3. **Reveal the molecular mechanism by which DNMT3B inhibits PLCG2**: Analyze how DNMT3B inhibits the transcription of PLCG2 by methylating the promoter region of PLCG2 through methylation - specific PCR (MSP) and bisulfite sequencing PCR (BSP). 4. **Evaluate the influence of PLCG2 over - expression on colorectal cancer cell proliferation**: Construct a stable cell line with PLCG2 over - expression and conduct cell proliferation experiments (such as colony - formation experiment, CCK - 8 experiment, etc.) to evaluate the inhibitory effect of PLCG2 on colorectal cancer cell proliferation. 5. **Verify the function of the DNMT3B - PLCG2 pathway in vivo**: Observe the inhibitory effect of PLCG2 over - expression on tumor growth in vivo through xenograft experiments. In summary, this paper aims to clarify the molecular mechanism by which DNMT3B inhibits PLCG2 expression by methylating the promoter region of PLCG2, thereby promoting colorectal cancer cell proliferation, and provide new targets and strategies for the treatment of colorectal cancer.